TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26019129

Group type: EXPERIMENTAL
Intervention: CYP2C19 intermediate or poor metabolizer status
Number of subjects: 522

Group type: COMPARATOR
Intervention: CYP2C19 extensive or ultrarapid metabolizer status
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype-inferred metabolizer status
Number of subjects: 522
Study: 23999502

Group type: EXPERIMENTAL
Intervention: Multi-level and multi-component interventions
Number of subjects: 1700
Study: 21876313

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-dose MMF
Number of subjects: 40
Study: 19616297

Group type: EXPERIMENTAL
Intervention: Intact dentin
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Prepared but unobturated canal
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Canal obturated with epoxy resin (AH Plus/gutta percha)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Canal obturated with UDMA resin sealer (Resilon/RealSeal)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Wf perpendicular to tubule direction
Number of subjects: 70
Study: 16920249

Group type: EXPERIMENTAL
Intervention: Cyclogest 400mg
Number of subjects: 132

Group type: COMPARATOR
Intervention: Endometrin 100mg
Number of subjects: 132
Study: 15313807

Group type: EXPERIMENTAL
Intervention: Hospital education plus tailored materials and telephone counseling
Number of subjects: 108

Group type: COMPARATOR
Intervention: Hospital education alone
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 108
Study: 12893374

Group type: EXPERIMENTAL
Intervention: 500 microg neostigmine in the axillary plexus (NAGr)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline solution (1 ml) in the axillary plexus (TGr)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 500 microg neostigmine subcutaneously (NSGr)
Number of subjects: 90
Study: 10428228

Group type: EXPERIMENTAL
Intervention: Intermittent clamping of suction drains (clamped 55 minutes each hour, released for 5 minutes each hour for 6 hours postoperatively)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intermittent clamping of suction drains
Number of subjects: 54

Group type: COMPARATOR
Intervention: Free drainage
Number of subjects: 54
Study: 7744234

Group type: EXPERIMENTAL
Intervention: Insulin doses
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 24-h mean serum insulin
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 24-h mean serum insulin and HbA1c concentration
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Insulin values at 03.00 hours
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Insulin values at 07.00 hours
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Night-time hypoglycaemia
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Correlation of insulin profiles
Number of subjects: 77
Study: 1963071

Group type: EXPERIMENTAL
Intervention: alpha-2a interferon
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 7028181

Group type: EXPERIMENTAL
Intervention: COPP (cyclophosphamide, vincristine, procarbazine, prednisone)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: BCVP (BCNU, cyclophosphamide, vincristine, prednisone)
Number of subjects: 52

Group type: COMPARATOR
Intervention: CP (cyclophosphamide-prednisone)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: COPP
Number of subjects: 52
Study: 31155169

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine (1 mg/kg)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Intravenous fentanyl (1 μg/kg)
Number of subjects: 130
Study: 29724749

Group type: EXPERIMENTAL
Intervention: Emollient bath additives
Number of subjects: 482

Group type: COMPARATOR
Intervention: No bath additives
Number of subjects: 482
Study: 27977797

Group type: EXPERIMENTAL
Intervention: Recombinant HBV vaccine (3 or 4 doses)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination strategies
Number of subjects: 364
Study: 24754047

Group type: EXPERIMENTAL
Intervention: G-CSF treatment (Group A)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo treatment (Group B)
Number of subjects: 47
Study: 22729705

Group type: EXPERIMENTAL
Intervention: Suture mesh fixation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Tacker mesh fixation
Number of subjects: 110
Study: 20854735

Group type: EXPERIMENTAL
Intervention: Xuebijing injection (100 ml once daily for 7 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Xuebijing injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 30
Study: 18715204

Group type: EXPERIMENTAL
Intervention: NovoPen 4
Number of subjects: 35
Study: 15985478

Group type: EXPERIMENTAL
Intervention: Metyrapone (750 mg every 4 h for 24 h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 12024097

Group type: EXPERIMENTAL
Intervention: Prone Position (PP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Supine Position (SP)
Number of subjects: 51
Study: 10751856

Group type: EXPERIMENTAL
Intervention: Saw palmetto herbal blend
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 9015907

Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (400 micrograms daily)
Number of subjects: 24
Study: 1642836

Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin hydrochloride (250 mg/mL in saline solution, four drops administered locally twice a day for 5 to 10 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intramuscular gentamicin sulfate (80 mg administered intramuscularly twice a day for 5 to 10 days)
Number of subjects: 60
Study: 6526772

Group type: EXPERIMENTAL
Intervention: Padded helmet
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Padded helmet and padded slippers
Number of subjects: 1

Group type: COMPARATOR
Intervention: No protective clothing
Number of subjects: 1
Study: 31594878

Group type: EXPERIMENTAL
Intervention: De-implementation strategies to reduce test ordering
Number of subjects: 39
Study: 29660207

Group type: EXPERIMENTAL
Intervention: Aripiprazole/sertraline combination (ASC)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo/sertraline combination (PSC)
Number of subjects: 412
Study: 27388435

Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy (smelled for 20 minutes twice a day over a 12-week period)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diluted milk (control group)
Number of subjects: 100
Study: 23921488

Group type: EXPERIMENTAL
Intervention: Focalin XR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concerta
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritalin LA
Number of subjects: 0
Study: 22194373

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) with distal filter protection
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fibrolipid plaques
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fibrocalcified plaques
Number of subjects: 50
Study: 20416130

Group type: EXPERIMENTAL
Intervention: Dietary advice (DG; n=29)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Daily iron supplement with meals (SG; n=23; 50 mg Fe as amino acid chelate)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (PG; n=26)
Number of subjects: 78
Study: 18582928

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily for 31-39 days (with placebo injection for 10-14 days)
Number of subjects: 2509

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily subcutaneously for 10-14 days (with placebo tablet for 31-39 days)
Number of subjects: 2509

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 2509

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 2509
Study: 15981045

Group type: EXPERIMENTAL
Intervention: Nasoenteric feeding (test group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 12054909

Group type: EXPERIMENTAL
Intervention: ozagrel hydrochloride (400 mg for 4 days)
Number of subjects: 4

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 4
Study: 10740407

Group type: EXPERIMENTAL
Intervention: Nephrotic syndrome patients
Number of subjects: 21
Study: 7626851

Group type: EXPERIMENTAL
Intervention: Chronotherapy with 5-FU, folinic acid, and oxaliplatin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chronotherapy with 5-FU
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cytokine delivery (interferon alpha)
Number of subjects: 50
Study: 8382753

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor, lisinopril (ACEI)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Calcium antagonist, nifedipine (CA)
Number of subjects: 25
Study: 3533082

Group type: EXPERIMENTAL
Intervention: Conventional group psychotherapy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Group assertion/relaxation training
Number of subjects: 57

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 57
Study: 31416333

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nadolol
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 28750917

Group type: EXPERIMENTAL
Intervention: pegylated interferon (PEG-IFN) therapy
Number of subjects: 121
Study: 27616607

Group type: EXPERIMENTAL
Intervention: Virtual reality dodgeball intervention (15 minutes for 3 consecutive days)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 52
Study: 25318408

Group type: EXPERIMENTAL
Intervention: Sufentanil sublingual tablet system (SSTS) dispensing a 15-μg sufentanil tablet sublingually with a 20-minute lockout
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sufentanil sublingual tablet system (SSTS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23871270

Group type: EXPERIMENTAL
Intervention: LeFort I surgery
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Late maxillary protraction
Number of subjects: 32

Group type: COMPARATOR
Intervention: Combined treatments (surgery and protraction)
Number of subjects: 32
Study: 21410370

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1800

Group type: COMPARATOR
Intervention: PCI
Number of subjects: 1800
Study: 19505827

Group type: EXPERIMENTAL
Intervention: Sinusoidal oscillation of an immersive virtual scene at 188 cm/s
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sinusoidal oscillation of an immersive virtual scene at 125 cm/s
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sinusoidal oscillation of an immersive virtual scene at lower velocities (1.2 to 125 cm/s)
Number of subjects: 10
Study: 17011559

Group type: EXPERIMENTAL
Intervention: Sperm protamine‐1 (P1) and protamine‐2 (P2) concentrations
Number of subjects: 0
Study: 15496650

Group type: EXPERIMENTAL
Intervention: Corydalis yanhusuo and Angelicae dahuricae extracts, single oral administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11132399

Group type: EXPERIMENTAL
Intervention: N2O + hyperventilation (HV)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: O2/air + hyperventilation (HV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: N2O + normoventilation (NV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: O2/air + normoventilation (NV)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 40
Study: 9681529

Group type: EXPERIMENTAL
Intervention: BrdUrd assay
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: PCNA assay
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: PCNA PH
Number of subjects: 390
Study: 7801065

Group type: EXPERIMENTAL
Intervention: Low power Ga-Al-As laser treatment (22.5 joule per treatment, 15 min each, total of nine treatments over 9 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo laser treatment
Number of subjects: 29
Study: 3288682

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (200-800 micrograms daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Budesonide (200-800 micrograms daily)
Number of subjects: 30
Study: 29608590

Group type: EXPERIMENTAL
Intervention: ceftriaxone/doxycycline (n = 82)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: ceftriaxone/clarithromycin-hydroxychloroquine (n = 93)
Number of subjects: 271

Group type: COMPARATOR
Intervention: ceftriaxone/placebo (n = 96)
Number of subjects: 271

Group type: COMPARATOR
Intervention: ceftriaxone/doxycycline compared to ceftriaxone/placebo
Number of subjects: 271

Group type: COMPARATOR
Intervention: ceftriaxone/clarithromycin-hydroxychloroquine compared to ceftriaxone/placebo
Number of subjects: 271
Study: 27269205

Group type: EXPERIMENTAL
Intervention: Sequential bilateral rTMS (600 pulses at 1 Hz followed by 1500 pulses at 10 Hz)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Unilateral high-frequency left (HFL)-rTMS (2100 pulses at 10 Hz)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: All groups (bilateral, HFL-rTMS, sham)
Number of subjects: 121
Study: 23638947

Group type: EXPERIMENTAL
Intervention: Transmandibular implant
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Augmentation of the mandible with an autologous bone graft followed by placement of four endosseous implants
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Short endosseous implants
Number of subjects: 60
Study: 22448738

Group type: EXPERIMENTAL
Intervention: Avanafil 100 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Avanafil 200 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 20429382

Group type: EXPERIMENTAL
Intervention: Uvulopalatopharyngoplasty (UPPP)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Radio frequency plasma Uvulopalatopharyngoplasty
Number of subjects: 81
Study: 18522670

Group type: EXPERIMENTAL
Intervention: Evidence-based quality improvement (EBQI) approach to smoking cessation guidelines implementation
Number of subjects: 1941

Group type: COMPARATOR
Intervention: Usual care (mailed guidelines and VA audit-feedback reports)
Number of subjects: 1941
Study: 16422307

Group type: EXPERIMENTAL
Intervention: Bayesian designs for monitoring time to severe adverse event, disease progression, and death.
Number of subjects: 0
Study: 12201973

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (Carmeda or Duraflo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-heparin-coated circuits)
Number of subjects: 0
Study: 9681885

Group type: EXPERIMENTAL
Intervention: 8 Gy single dose
Number of subjects: 241

Group type: COMPARATOR
Intervention: 5 Gy x4 fractionated dose
Number of subjects: 241
Study: 2655366

Group type: EXPERIMENTAL
Intervention: 4 ml 0.5% bupivacaine in 8% glucose (hyperbaric) with 60 min sitting (Group-60)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4 ml 0.5% bupivacaine in 8% glucose (hyperbaric) with 2 min sitting (Group-2)
Number of subjects: 12
Study: 792688

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30830929

Group type: EXPERIMENTAL
Intervention: Insecticide-impregnated collars for dogs
Number of subjects: 6440

Group type: COMPARATOR
Intervention: Control (uncollared villages)
Number of subjects: 6440
Study: 27739217

Group type: EXPERIMENTAL
Intervention: CNRB
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: PRF
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: CNRB + PRF
Number of subjects: 62
Study: 25580933

Group type: EXPERIMENTAL
Intervention: Vigorous exercise as a treatment strategy
Number of subjects: 290

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 290
Study: 24624380

Group type: EXPERIMENTAL
Intervention: HP 7.5% (home application)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HP 35% (in-office application)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (immersion in deionised water)
Number of subjects: 60
Study: 21390543

Group type: EXPERIMENTAL
Intervention: High-intensity strength training
Number of subjects: 8
Study: 19131891

Group type: EXPERIMENTAL
Intervention: DAART (n = 88)
Number of subjects: 141

Group type: COMPARATOR
Intervention: SAT (n = 53)
Number of subjects: 141
Study: 17971595

Group type: EXPERIMENTAL
Intervention: Arzoxifene 20 mg daily
Number of subjects: 352

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg daily
Number of subjects: 352
Study: 15049934

Group type: EXPERIMENTAL
Intervention: Repaglinide plus rosiglitazone
Number of subjects: 252

Group type: COMPARATOR
Intervention: Repaglinide
Number of subjects: 252

Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 252
Study: 11430936

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2 g daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9601653

Group type: EXPERIMENTAL
Intervention: CNTF null mutation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8306551

Group type: EXPERIMENTAL
Intervention: Methylprednisolone pretreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No glucocorticoids (Control)
Number of subjects: 0
Study: 3407868

Group type: EXPERIMENTAL
Intervention: Neostigmine 30 micrograms/kg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Neostigmine 60 micrograms/kg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Neostigmine 80 micrograms/kg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Neostigmine (any dose)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Neostigmine 60 micrograms/kg and 80 micrograms/kg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Neostigmine and glycopyrronium (fixed 5:1 ratio)
Number of subjects: 27
Study: 686346

Group type: EXPERIMENTAL
Intervention: Enflurane concentrations ranging from 0.5 to 2.0 vol.%
Number of subjects: 10

Group type: COMPARATOR
Intervention: Neuroleptanaesthesia (control)
Number of subjects: 10
Study: 30892997

Group type: EXPERIMENTAL
Intervention: Advance care planning (ACP) and usual care
Number of subjects: 141

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 141
Study: 28951711

Group type: EXPERIMENTAL
Intervention: Intervention group (advised about urinary cotinine levels by telephone)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Non-intervention group (not advised about urinary cotinine levels)
Number of subjects: 134
Study: 25858202

Group type: EXPERIMENTAL
Intervention: High tryptophan diet
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low tryptophan diet
Number of subjects: 25
Study: 22771287

Group type: EXPERIMENTAL
Intervention: Supervising for Home Safety program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control program focusing on child nutrition and active lifestyles
Number of subjects: 0
Study: 22764361

Group type: EXPERIMENTAL
Intervention: Foster care
Number of subjects: 208

Group type: COMPARATOR
Intervention: Usual care (institutional care)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Never-institutionalized
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Foster care (early placement before age 24 months)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Lower baseline cognitive ability
Number of subjects: 208
Study: 20494902

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Amlodipine + Atorvastatin
Number of subjects: 311
Study: 16919926

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mcg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oxitropium 800 mcg/day
Number of subjects: 80
Study: 15613428

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 mug)
Number of subjects: 931

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 931
Study: 12214543

Group type: EXPERIMENTAL
Intervention: Dietary supplement of live Lactobacillus acidophilus and Lactobacillus Casei, 10(7)‐10(8)/ml in fermented milk (LB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fluid milk (L) as control
Number of subjects: 100
Study: 9626806

Group type: COMPARATOR
Intervention: rhGM-CSF
Number of subjects: 51

Group type: COMPARATOR
Intervention: rhG-CSF
Number of subjects: 51

Group type: COMPARATOR
Intervention: No cytokines
Number of subjects: 51
Study: 7710150

Group type: EXPERIMENTAL
Intervention: 2 mg aerosolized glycopyrrolate
Number of subjects: 57

Group type: COMPARATOR
Intervention: Aerosolized placebo
Number of subjects: 57
Study: 2651013

Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan-peptide complex (Rumalon), administered as intramuscular injections of 3 x 2 ml ampoules per week for 8 weeks, alternating with 8-week periods free of trial medication
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan-peptide complex (Rumalon)
Number of subjects: 62
Study: 646918

Group type: EXPERIMENTAL
Intervention: Extradural anaesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (Extradural and General anaesthesia)
Number of subjects: 0
Study: 30859297

Group type: EXPERIMENTAL
Intervention: TachoSil® (collagen-fibrin sealant patch)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard closure without collagen-fibrin sealant patch
Number of subjects: 19
Study: 27973336

Group type: EXPERIMENTAL
Intervention: Aspirin alone (ASA) as post-implantation antithrombotic treatment
Number of subjects: 107
Study: 25923820

Group type: EXPERIMENTAL
Intervention: Single-Injection (SI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Triple-Injection (TI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both SI and TI
Number of subjects: 100
Study: 22129607

Group type: EXPERIMENTAL
Intervention: Valsartan + Amlodipine (V‐A) 160/5 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Valsartan + Hydrochlorothiazide (V‐H) 160/12.5 mg
Number of subjects: 60
Study: 20514078

Group type: EXPERIMENTAL
Intervention: Diltiazem coadministered with tacrolimus in CYP3A5 expressers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Algorithm-guided dosing for CYP3A5 expressers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dosing for CYP3A5 nonexpressers
Number of subjects: 0